

**EP246**

**68Ga-PSMA PET/CT in Biochemical Relapsed Prostate Cancer - Initial Experience**

R. Silva<sup>1,2</sup>, A. Abrunhosa<sup>2</sup>, A. Figueiredo<sup>1</sup>, Â. Cruz<sup>2</sup>, A. Xavier<sup>2</sup>, D. Barroca<sup>2</sup>, M. Castelo Branco<sup>2</sup>, J. Pedroso de Lima<sup>1,2</sup>; <sup>1</sup>Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL, <sup>2</sup>Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL.

**EP247**

**Early and Late Imaging of Choline PET/CT for the Detection of Prostatic Fossae Recurrences in Prostate Cancer with a Biochemical Failure (PSA < 2 ng/mL)**

L. Evangelista<sup>1</sup>, M. Hodolic<sup>2</sup>, M. Burei<sup>1</sup>, E. Pizzirani<sup>3</sup>, G. Ramondo<sup>3</sup>, G. Saladini<sup>1</sup>; <sup>1</sup>Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, ITALY, <sup>2</sup>Nuclear Medicine Research Department, IASON, Graz, AUSTRIA, <sup>3</sup>Radiology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, ITALY.

**EP248**

**18FDG-PET/CT hypermetabolic renal bed granuloma post-nephrectomy mimicking local recurrence in renal cancer**

G. L. Bruno, G. L. Bruno; FCDN, Buenos Aires, ARGENTINA.

**EP249**

**Value of 18F-FDG PET/CT in patients with castration resistant prostate cancer**

M. Grmek, S. Hawlina, L. Lezaic; University Medical Centre Ljubljana, LJUBLJANA, SLOVENIA.

**EP250**

**18F-Choline PET-CT findings in prostate cancer recurrence and treatment modality**

L. Mohamed Salem, Sr., A. Abella Tarazona, M. Ibañez Ibañez, V. Godoy Bravo, R. Reyes Marles, I. Sime Loayza, J. Navarro Fernandez, L. Frutos Esteban, M. Castellón Sanchez, F. Nicolas Ruiz, P. López Cubillana, F. López Soler, P. López González, M. Porras Martinez, M. Claver Valderas; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

**EP251**

**Dual-Time Point Evaluation of Prostate Cancer Lesions detected by <sup>68</sup>Ga-PSMA PET/CT**

L. Sobral Violante, I. Sampaio, J. Teixeira, G. Ferreira, H. Duarte; 1 Instituto Português de Oncologia, Porto, PORTUGAL.

**EP252**

**Detection of primary and metastatic lesions of urinary tract tumors by <sup>18</sup>F-FLT PET/CT**

K. Kato<sup>1</sup>, Y. Koshiba<sup>1</sup>, K. Kunitomo<sup>1</sup>, M. Honda<sup>1</sup>, A. Murai<sup>1</sup>, S. Abe<sup>2</sup>, T. Odagawa<sup>1</sup>, S. Naganawa<sup>1</sup>; <sup>1</sup>Nagoya University Graduate School of Medicine, Nagoya, JAPAN, <sup>2</sup>Nagoya University Hospital, Nagoya, JAPAN.

**EP253**

**C11-choline PET/CT is an effective tool in prostate cancer diagnosis**

I. Garai<sup>1</sup>, A. Káplár<sup>1</sup>, B. Farkas<sup>1</sup>, C. Berczi<sup>2</sup>; <sup>1</sup>ScanoMed Ltd, University of Debrecen, Debrecen, HUNGARY, <sup>2</sup>Department of Urology, University of Debrecen, Debrecen, HUNGARY.

**EP254**

**The Burden of Castrate-Resistant Prostate Cancer: Making a Case for PSMA Targeted Therapy in Southwest Nigeria**

Y. A. Onimode<sup>1,2</sup>, A. T. Orunmuyi<sup>1,2</sup>, B. O. A. OSIFO<sup>2</sup>; <sup>1</sup>University of Ibadan, Ibadan, NIGERIA, <sup>2</sup>Nuclear Medicine Centre, University College Hospital, Ibadan, NIGERIA.

**EP255**

**Impact of 18F-Choline PET-CT on the selection of patients with oligometastatic prostate cancer recurrence candidates for local salvage treatments**

I. L. Fernandez-Tercero, A. Gomez-Iturriaga, A. Sanchez-Salmon, F. Casquero, A. Urresola, A. I. Ezquerro, R. Larena, E. Rodeño; Cruces University Hospital, Baracaldo(Bizkaia), SPAIN.

**EP256**

**qPET Distribution in Prostate, Lymphonodular and Skeletal FCH-PET Positivities in Biological Relapse of Prostate Carcinoma**

C. Olianti<sup>1</sup>, M. Di Russo<sup>1</sup>, I. Laghai<sup>1</sup>, M. R. Raspollini<sup>2</sup>, F. Sessa<sup>3</sup>, A. Minervini<sup>3</sup>; <sup>1</sup>Nuclear Medicine Unit, Florence, ITALY, <sup>2</sup>Pathologic Histology Unit, Florence, ITALY, <sup>3</sup>Clinic Urology Unit, Florence, ITALY.

**EP257**

**Computer-assisted analysis of skeletal lesions in the staging of prostate cancer: Prospective multicenter study**

L. J. Petersen<sup>1</sup>, J. C. Mortensen<sup>2</sup>, H. Bertelsen<sup>1</sup>, H. D. Zacho<sup>1</sup>; <sup>1</sup>Aalborg University Hospital, Aalborg, DENMARK, <sup>2</sup>Regional Hospital West Jutland, Herning, DENMARK.